Clinical Trials
11
Active:0
Completed:9
Trial Phases
2 Phases
Phase 3:2
Phase 4:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 4
4 (66.7%)Phase 3
2 (33.3%)A Study of Pharmacodynamic and Genetic Parameters of Abira-DES Study Participants (NCT02217566) - Participants With Metastatic Castration-Resistant Prostate Cancer Treated With Abiraterone Acetate Following Unresponsive Treatment With Diethylstilbestrol
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- First Posted Date
- 2020-02-13
- Last Posted Date
- 2022-01-03
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 42
- Registration Number
- NCT04268628
- Locations
- 🇧🇷
Sociedade Beneficiante de Senhoras - Hospital Sirio Libanes, São Paulo, Brazil
A Study to Evaluate Virologic Response in Participants Newly Diagnosed With HIV-1
Completed
- Conditions
- HIV
- Interventions
- Drug: Antiretroviral Therapy
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-12-11
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 105
- Registration Number
- NCT04147325
- Locations
- 🇵🇹
Chlo - Hosp. Egas Moniz, Lisboa, Portugal
A Study to Analyze the Impact of Treatment With Paliperidone Palmitate on Clinical Outcomes and Hospital Resource Utilization in Adult Participants With Schizophrenia in Portugal
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: Oral Antipsychotics (OAPs)
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 55
- Registration Number
- NCT03666715
- Locations
- 🇵🇹
Neurobios , Instituto De Neurociências, Porto, Portugal
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
- Conditions
- B-cell Chronic Lymphocytic Leukemia
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Registration Number
- NCT02437019
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2014-09-18
- Lead Sponsor
- Janssen-Cilag Farmaceutica Ltda.
- Target Recruit Count
- 142
- Registration Number
- NCT01448720
- Prev
- 1
- 2
- 3
- Next
News
No news found